These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

837 related items for PubMed ID: 20647171

  • 1. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial.
    Diener HC, Dodick DW, Aurora SK, Turkel CC, DeGryse RE, Lipton RB, Silberstein SD, Brin MF, PREEMPT 2 Chronic Migraine Study Group.
    Cephalalgia; 2010 Jul; 30(7):804-14. PubMed ID: 20647171
    [Abstract] [Full Text] [Related]

  • 2. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial.
    Aurora SK, Dodick DW, Turkel CC, DeGryse RE, Silberstein SD, Lipton RB, Diener HC, Brin MF, PREEMPT 1 Chronic Migraine Study Group.
    Cephalalgia; 2010 Jul; 30(7):793-803. PubMed ID: 20647170
    [Abstract] [Full Text] [Related]

  • 3. OnabotulinumtoxinA for treatment of chronic migraine: pooled analyses of the 56-week PREEMPT clinical program.
    Aurora SK, Winner P, Freeman MC, Spierings EL, Heiring JO, DeGryse RE, VanDenburgh AM, Nolan ME, Turkel CC.
    Headache; 2011 Oct; 51(9):1358-73. PubMed ID: 21883197
    [Abstract] [Full Text] [Related]

  • 4. OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program.
    Dodick DW, Turkel CC, DeGryse RE, Aurora SK, Silberstein SD, Lipton RB, Diener HC, Brin MF, PREEMPT Chronic Migraine Study Group.
    Headache; 2010 Jun; 50(6):921-36. PubMed ID: 20487038
    [Abstract] [Full Text] [Related]

  • 5. OnabotulinumtoxinA for chronic migraine: efficacy, safety, and tolerability in patients who received all five treatment cycles in the PREEMPT clinical program.
    Aurora SK, Dodick DW, Diener HC, DeGryse RE, Turkel CC, Lipton RB, Silberstein SD.
    Acta Neurol Scand; 2014 Jan; 129(1):61-70. PubMed ID: 24107267
    [Abstract] [Full Text] [Related]

  • 6. OnabotulinumtoxinA for treatment of chronic migraine: PREEMPT 24-week pooled subgroup analysis of patients who had acute headache medication overuse at baseline.
    Silberstein SD, Blumenfeld AM, Cady RK, Turner IM, Lipton RB, Diener HC, Aurora SK, Sirimanne M, DeGryse RE, Turkel CC, Dodick DW.
    J Neurol Sci; 2013 Aug 15; 331(1-2):48-56. PubMed ID: 23790235
    [Abstract] [Full Text] [Related]

  • 7. OnabotulinumtoxinA improves quality of life and reduces impact of chronic migraine.
    Lipton RB, Varon SF, Grosberg B, McAllister PJ, Freitag F, Aurora SK, Dodick DW, Silberstein SD, Diener HC, DeGryse RE, Nolan ME, Turkel CC.
    Neurology; 2011 Oct 11; 77(15):1465-72. PubMed ID: 21956721
    [Abstract] [Full Text] [Related]

  • 8. Per cent of patients with chronic migraine who responded per onabotulinumtoxinA treatment cycle: PREEMPT.
    Silberstein SD, Dodick DW, Aurora SK, Diener HC, DeGryse RE, Lipton RB, Turkel CC.
    J Neurol Neurosurg Psychiatry; 2015 Sep 11; 86(9):996-1001. PubMed ID: 25500317
    [Abstract] [Full Text] [Related]

  • 9. OnabotulinumtoxinA improves quality of life and reduces impact of chronic migraine over one year of treatment: Pooled results from the PREEMPT randomized clinical trial program.
    Lipton RB, Rosen NL, Ailani J, DeGryse RE, Gillard PJ, Varon SF.
    Cephalalgia; 2016 Aug 11; 36(9):899-908. PubMed ID: 27288354
    [Abstract] [Full Text] [Related]

  • 10. Early onset of effect of onabotulinumtoxinA for chronic migraine treatment: Analysis of PREEMPT data.
    Dodick DW, Silberstein SD, Lipton RB, DeGryse RE, Adams AM, Diener HC.
    Cephalalgia; 2019 Jul 11; 39(8):945-956. PubMed ID: 31112399
    [Abstract] [Full Text] [Related]

  • 11. OnabotulinumtoxinA (BOTOX®): a review of its use in the prophylaxis of headaches in adults with chronic migraine.
    Frampton JE.
    Drugs; 2012 Apr 16; 72(6):825-45. PubMed ID: 22468643
    [Abstract] [Full Text] [Related]

  • 12. Botulinum toxin type A (BOTOX) for the prophylactic treatment of chronic daily headache: a randomized, double-blind, placebo-controlled trial.
    Mathew NT, Frishberg BM, Gawel M, Dimitrova R, Gibson J, Turkel C, BOTOX CDH Study Group.
    Headache; 2005 Apr 16; 45(4):293-307. PubMed ID: 15836565
    [Abstract] [Full Text] [Related]

  • 13. Sustained benefits of onabotulinumtoxinA treatment in chronic migraine: An analysis of the pooled Phase 3 REsearch Evaluating Migraine Prophylaxis Therapy (PREEMPT) randomized controlled trials.
    Silberstein SD, Diener HC, Dodick DW, Sommer K, Lipton RB.
    Headache; 2024 Apr 16; 64(7):838-848. PubMed ID: 38982666
    [Abstract] [Full Text] [Related]

  • 14. A multi-center double-blind pilot comparison of onabotulinumtoxinA and topiramate for the prophylactic treatment of chronic migraine.
    Cady RK, Schreiber CP, Porter JA, Blumenfeld AM, Farmer KU.
    Headache; 2011 Jan 16; 51(1):21-32. PubMed ID: 21070228
    [Abstract] [Full Text] [Related]

  • 15. Assessing clinically meaningful treatment effects in controlled trials: chronic migraine as an example.
    Dodick DW, Turkel CC, DeGryse RE, Diener HC, Lipton RB, Aurora SK, Nolan ME, Silberstein SD.
    J Pain; 2015 Feb 16; 16(2):164-75. PubMed ID: 25464159
    [Abstract] [Full Text] [Related]

  • 16. A Randomized Trial to Evaluate OnabotulinumtoxinA for Prevention of Headaches in Adolescents With Chronic Migraine.
    Winner PK, Kabbouche M, Yonker M, Wangsadipura V, Lum A, Brin MF.
    Headache; 2020 Mar 16; 60(3):564-575. PubMed ID: 32037549
    [Abstract] [Full Text] [Related]

  • 17. The impact of onabotulinumtoxinA on severe headache days: PREEMPT 56-week pooled analysis.
    Matharu M, Halker R, Pozo-Rosich P, DeGryse R, Manack Adams A, Aurora SK.
    J Headache Pain; 2017 Dec 16; 18(1):78. PubMed ID: 28766236
    [Abstract] [Full Text] [Related]

  • 18. Pooled analysis of the safety and tolerability of onabotulinumtoxinA in the treatment of chronic migraine.
    Diener HC, Dodick DW, Turkel CC, Demos G, Degryse RE, Earl NL, Brin MF.
    Eur J Neurol; 2014 Jun 16; 21(6):851-9. PubMed ID: 24628923
    [Abstract] [Full Text] [Related]

  • 19. Effects of onabotulinumtoxinA treatment in chronic migraine patients with and without daily headache at baseline: results from the COMPEL Study.
    Young WB, Ivan Lopez J, Rothrock JF, Orejudos A, Manack Adams A, Lipton RB, Blumenfeld AM.
    J Headache Pain; 2019 Feb 01; 20(1):12. PubMed ID: 30709333
    [Abstract] [Full Text] [Related]

  • 20. Botulinum toxin type a for the prophylaxis of chronic daily headache: subgroup analysis of patients not receiving other prophylactic medications: a randomized double-blind, placebo-controlled study.
    Dodick DW, Mauskop A, Elkind AH, DeGryse R, Brin MF, Silberstein SD, BOTOX CDH Study Group.
    Headache; 2005 Apr 01; 45(4):315-24. PubMed ID: 15836567
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 42.